Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But analysts caution that insurers have incomplete data on medical costs in the first quarter due to a lag in claims processing, which sets up the second quarter as the real proving ground.
CI beats Q1 EPS estimates as Evernorth revenues jump 9% despite rising pharmacy costs; 2026 EPS outlook lifted to at least $30.35.
The Cigna Group (CI) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna Group will exit the Affordable Care Act market next year, citing an effort to focus on other lines of business.
The Cigna Group Thursday confirmed plans to exit the individual health insurance business also known as Obamacare next year, leaving about 369,00 health plan members in 11 states looking for new coverage in 2027.
Cigna (CI) came out with quarterly earnings of $7.79 per share, beating the Zacks Consensus Estimate of $7.62 per share. This compares to earnings of $6.74 per share a year ago.
Cigna Group logged higher profit and revenue in its latest quarter as its pharmacy-benefit business Evernorth continued to grow.
Cigna slightly raised its annual adjusted profit forecast on Thursday after beating first-quarter earnings estimates, helped by strength in its health services unit and as medical costs came in lower than expected.
Get a deeper insight into the potential performance of Cigna (CI) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
CI approaches Q1 results with strong pharmacy growth but a steep premium drop, as estimates point to mixed year-over-year performance.